EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients

Identification of epidermal growth factor receptor (EGFR) as a molecular target has radically changed the treatment of metastatic non-small cell lung cancer (NSCLC) from standard chemotherapy to personalized, targeted therapy. First-, second- and third-generation EGFR tyrosine kinase inhibitors (TKI...

Descripción completa

Detalles Bibliográficos
Autores principales: Karachaliou, Niki, Fernandez-Bruno, Manuel, Bracht, Jillian Wilhelmina Paulina, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797317/
https://www.ncbi.nlm.nih.gov/pubmed/35117062
http://dx.doi.org/10.21037/tcr.2018.10.06

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797317/
https://www.ncbi.nlm.nih.gov/pubmed/35117062
http://dx.doi.org/10.21037/tcr.2018.10.06

Ejemplares similares